November 29, 2020
SHALAKANY ACTS FOR GRIFOLS IN A STRATEGIC ALLIANCE WITH THE EGYPTIAN GOVERNMENT TO BOOST PLASMA-DERIVED MEDICINES SELF-SUFFICIENCY IN THE MIDDLE EAST AND AFRICA
Cairo, Egypt – Shalakany is delighted to announce that they have acted as local counsel for Grifols (one of the world’s leading producers of plasma-derived medicines) in a strategic alliance with the Egyptian government, through the National Service Projects Organization (“NSPO”), to boost plasma-derived medicines self-sufficiency in the Middle East and Africa.
On 24 November 2020, Grifols and NSPO signed a strategic agreement (Master Joint Venture Agreement) to further develop the Egyptian plasma-derivatives market and promote its self-sufficiency. Under this joint venture, owned by Grifols (49%) and NSPO (51%), the parties will join their industrial expertise and financial efforts for the development, construction and operation of 20 plasma collection centers throughout Egypt (with an initial capacity to collect 600,000 liters of plasma per year); manufacturing facilities, including a fractionation plant (with a capacity to fractionate up to 1 million liters of plasma per year) and a purification and fill-and-finish plant; a warehouse and an analysis laboratory. The plasma centers and manufacturing installations are expected to be operational at the end of 2025. The total expected capital expenditure for the project is estimated to be USD 300 million.
Aly El Shalakany, the Grifols relationship partner, said: “We are proud to have supported our client in this landmark national project which pairs Grifols’ unique expertise and Egypt’s distinctive capabilities. This project will achieve plasma self-sufficiency for Egypt and its citizens and establish Egypt as a regional and global supplier of plasma. I would like to express my congratulations to all of the stakeholders for reaching this successful and historic signing.”
On 24 November 2020, Grifols and NSPO signed a strategic agreement (Master Joint Venture Agreement) to further develop the Egyptian plasma-derivatives market and promote its self-sufficiency. Under this joint venture, owned by Grifols (49%) and NSPO (51%), the parties will join their industrial expertise and financial efforts for the development, construction and operation of 20 plasma collection centers throughout Egypt (with an initial capacity to collect 600,000 liters of plasma per year); manufacturing facilities, including a fractionation plant (with a capacity to fractionate up to 1 million liters of plasma per year) and a purification and fill-and-finish plant; a warehouse and an analysis laboratory. The plasma centers and manufacturing installations are expected to be operational at the end of 2025. The total expected capital expenditure for the project is estimated to be USD 300 million.
Aly El Shalakany, the Grifols relationship partner, said: “We are proud to have supported our client in this landmark national project which pairs Grifols’ unique expertise and Egypt’s distinctive capabilities. This project will achieve plasma self-sufficiency for Egypt and its citizens and establish Egypt as a regional and global supplier of plasma. I would like to express my congratulations to all of the stakeholders for reaching this successful and historic signing.”
